跳至主要内容
临床试验/NCT00223821
NCT00223821已完成不适用

Enhancing Conservative Treatment for Urge Incontinence

US Department of Veterans Affairs1 个研究点 分布在 1 个国家目标入组 166 人开始时间: 2003年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
166
试验地点
1
主要终点
Change in Incontinent Episodes Immediately Post-treatment

研究概览

简要总结

The primary objective of this project is to evaluate whether enhancing drug therapy with components of behavioral training, including pelvic floor muscle rehabilitation, results in better outcomes than drug therapy alone for urge incontinence in community-dwelling women.

详细描述

Urinary incontinence in women is a major problem with significant medical, psychological, and social consequences. Previous research on urge incontinence, a common form of incontinence, has demonstrated that behavioral and drug interventions are effective, but do not cure most patients. Thus there is a need to improve conservative treatment for urge incontinence in women. The primary objective of this project is to evaluate whether enhancing drug therapy with components of behavioral training, including pelvic floor muscle rehabilitation, results in better outcomes than drug therapy alone for urge incontinence in community-dwelling women. This project is a randomized controlled clinical trial. Sixty-four women with predominantly urge incontinence have been randomized. Stratification and blocked randomization procedures are used to assign a subject to 8 weeks of drug therapy alone or 8 weeks of drug therapy enhanced with components of behavioral training that can be administered in most any outpatient clinic. The drug therapy is extended release oxybutynin, a well-established pharmacologic agent with a state of the art drug delivery system that has the lowest rates of side-effect. The behavioral treatment is an innovative, comprehensive, behavioral training program, which includes pelvic floor muscle rehabilitation, teaching urge suppression and other skills to improve bladder control, and self-monitoring with bladder diaries. Bladder diaries completed by subjects before and after the treatment are used to calculate reduction in the frequency of incontinence. Secondary outcomes measures include a patient satisfaction questionnaire and three impact/quality of life measures (Incontinence Impact Questionnaire, Uro-Genital Distress Index, SF-12 Health Survey). The second objective of the study is to examine the cost-effectiveness of adding behavioral components to drug therapy. With the changing health care environment, there is increased concern with the costs of providing treatment. This project will compare the relative costs and value of combined intervention using the methods of cost-effectiveness analysis, the most widely adopted method for the economic evaluation of health interventions. The third objective of the study is to examine further the mechanisms by which these therapies reduce incontinence, including changes in bladder capacity, thresholds for bladder sensation, pelvic muscle strength, use of pelvic muscles in response to the sensation of urgency and frequency of urination. Pre-post changes in these parameters are measured to examine the effects of the treatment on these variables, and structural equation modeling will be used to examine whether changes in each of these measures are related to treatment outcome.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Participants in this study were ambulatory, community-dwelling women (veterans and nonveterans) with persistent urge or predominantly urge incontinence.
  • Participants must:
  • Be ambulatory.
  • Be able to come to the clinic for treatment.
  • Report urge incontinence.
  • Report incontinence occurring at least twice per week on average.
  • Report incontinence persisting for at least three months.
  • Not have received behavioral therapy in the University of Alabama at Birmingham (UAB) Continence Clinic or Department of Veterans Affairs (VA) Continence Clinic.
  • In the clinical interview, the subject must report involuntary loss of urine associated with a strong desire to void and that the condition has persisted for at least three months.
  • At least two urge accidents on the 7-day baseline bladder diary, and the number of urge accidents must exceed the number of other types of accidents.
  • On urodynamic evaluation, there must be cystometric evidence of bladder dysfunction, either: detrusor instability or maximal cystometric capacity is less than 400 ml.

排除标准

  • Continual leakage.
  • Urinary tract infection (defined as growth of greater than 10,000 colonies per ml of a urinary pathogen on urine culture).
  • Fecal impaction.
  • Uncontrolled metabolic problem.
  • Post-void residual volume > 150 ml.
  • Hematuria on microscopic examination in the absence of infection. A urologic consultation will be recommended and enrollment will depend on agreement between the urologist and geriatrician (co-PI) that entry into treatment protocol is not contraindicated.
  • Severe uterine prolapse (prolapse reaching the vaginal introitus).
  • Decompensated congestive heart failure, diagnosed by history or physical exam.
  • Impaired mental status. (<24 on Folstein's Mini-Mental State Exam).
  • Uncontrolled narrow angle glaucoma.
  • Gastric retention (by medical history).
  • Hypersensitivity to oxybutynin.
  • Current use of anticholinergic agents for detrusor instability. Subjects on these medications will be asked to discontinue them for the duration of the study. Evaluation will be delayed until the drug(s) have been discontinued for 2 weeks.
  • If on diuretic, dose stable for less than three months.

研究组 & 干预措施

Drug Therapy Aone

Active Comparator

Oxybutynin chloride, extended-release, individually-titrated

干预措施: Oxybutynin chloride, extended-release, individually-titrated (Drug)

Drug Therapy + Behavioral Training

Experimental

Drug Therapy + Behavioral Training: Individually-titrated, extended-release oxybutynin chloride with management of side-effects. Behavioral training consists of teaching urge suppression strategies and pelvic floor muscle training.

干预措施: Oxybutynin chloride, extended-release, individually-titrated (Drug)

Drug Therapy + Behavioral Training

Experimental

Drug Therapy + Behavioral Training: Individually-titrated, extended-release oxybutynin chloride with management of side-effects. Behavioral training consists of teaching urge suppression strategies and pelvic floor muscle training.

干预措施: Behavior Training (Behavioral)

结局指标

主要结局

Change in Incontinent Episodes Immediately Post-treatment

时间窗: Baseline and immediately post-treatment - week 8

Percent change from baseline in weekly frequency of incontinent episodes immediately post-treatment, derived from baseline and week 8 seven-day bladder diaries.

次要结局

  • Change in Incontinent Episodes at 12-month Follow-up(Baseline and 12 months post-treatment)

研究者

申办方类型
Fed
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Enhancing Conservative Treatment for Urge... | 临床试验